Acute leukaemias comprise approximately 32% of all childhood cancers (National Cancer Institute, 2018) . Up to 20% of paediatric patients with acute myeloid leukaemia (AML) have mutations in FLT3, conferring a poor prognosis (Balgobind et al, 2011; Zwaan et al, 2015) . Approximately 80% of infants with acute lymphoblastic leukaemia (ALL) have gene rearrangements in KMT2A (KMT2A-R ALL), often in combination with overexpression of mutation-negative FLT3 (Stam et al, 2007) . This combination of KMT2A-R ALL and FLT3 overexpression is associated with particularly poor long-term outcomes (Stam et al, 2007; Chillon et al, 2012) . Preclinical and clinical work suggests that targeted inhibition of FLT3 may be a promising strategy for paediatric acute leukaemias (Annesley & Brown, 2014) .
Midostaurin (PKC412), a multikinase inhibitor with targets that include FLT3, was approved in adults with newly diagnosed FLT3-mutated AML (Stone et al, 2017) . Midostaurin has demonstrated antileukaemic activity in preclinical models of FLT3-mutated AML and FLT3-overexpressing KMT2A-R ALL (Weisberg et al, 2002; Armstrong et al, 2003) . This dose-escalation and dose-expansion study evaluated the safety and efficacy of single-agent midostaurin in paediatric patients with relapsed or refractory (R/R) FLT3mutated AML or KMT2A-R ALL (NCT00866281). Patients had documented diagnosis of FLT3-mutated AML or KMT2A-R ALL according to local laboratory assessment. FLT3 mutations were confirmed at a central laboratory but were not required for inclusion of patients with KMT2A-R ALL. The primary objective was to determine the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) of oral midostaurin solution, developed for paediatric use, in each age group using a single 3-parameter Bayesian logistic regression model (Appendix S1). A dose-limiting toxicity (DLT) was defined as a nonhaematological grade 3/4 adverse event (AE), drug-related abnormal laboratory value, or AE leading to study discontinuation within 14 days of starting treatment occurring in the dose-determining set. Midostaurin was administered to children in 2 age groups: younger (≥3 months to ≤2 years) and older (>2 years to ≤18 years) ( Figure S1 ).
From September 2009 to October 2014, 22 patients were enrolled (9 FLT3-mutant AML, 13 KMT2A-R ALL). The study was terminated early due to slow accrual (Appendix S1). Baseline characteristics are presented in Table I and Table SI . All 9 patients with AML were in the older age group. Of 13 patients with KMT2A-R ALL, 11 were younger and 2 older. According to the central laboratory analysis of FLT3-mutation status, not all patients with AML had a FLT3 mutation (6 FLT3-internal tandem duplication, 1 FLT3-mutation-negative [FLT3-mutÀ], and 2 missing/ nonevaluable) and only 1 patient with KMT2A-R ALL had a FLT3 mutation (FLT3-tyrosine kinase domain; 11 FLT3-mutÀ; 1 missing/nonevaluable) (Table SII) . Potential reasons AML, acute myeloid leukaemia; KMT2A-R ALL, acute lymphoblastic leukaemia with KMT2A gene rearrangement. *Note that one patient with AML, who was considered as refractory to second induction therapy at the time of enrollment due to having received prior antineoplastic therapies, was initially incorrectly identified as previously untreated.
correspondence for discrepancy between the local and central laboratory analyses are discussed in the Supplementary Appendix. High levels of phosphorylated FLT3 were not detected in any patient sample (AML or KMT2A-R ALL) at baseline (Table SIII) . Of 22 patients, 7 (3 with FLT3-mutated AML and 4 with KMT2A-R ALL per local assessment) received the starting dose (30 mg/m 2 twice daily [bid]) and 15 (6 with FLT3mutated AML and 9 with KMT2A-R ALL per local assessment) received the maximum dose (60 mg/m 2 bid). All patients discontinued treatment ( Figure S2 ). No DLTs or significant safety concerns were observed among the 6 patients who received the 30 mg/m 2 bid dose; therefore, dose escalation proceeded to 60 mg/m 2 bid. Among 11 patients in the dose-determining set who received the 60 mg/m 2 bid dose, a DLT was reported in 1 patient (grade 3 alanine aminotransferase elevation). One patient with FLT3-mutated AML in the 60 mg/m 2 bid cohort completed the per-protocol followup; the remaining 21 patients died. Median duration of exposure to midostaurin for all patients was 16 days. Because the study design did not allow dosing beyond 60 mg/m 2 bid, a true MTD could not be determined and the 60 mg/m 2 bid dose was chosen as the RDE (Table SIV) .
Most patients (95Á5%) experienced ≥1 AE on treatment or during the 28-day follow-up period (Table SV) . Overall, 77Á3% of patients experienced grade 3/4 AEs, with more AEs occurring in the 60 mg/m 2 cohort than in the 30 mg/m 2 cohort. AEs suspected to be study treatment-related were reported in 72Á7% of patients.
Efficacy was evaluated in all 22 patients. The rate of best clinical response (assessed per modified Cheson criteria; Appendix S1) to single-agent midostaurin was 55Á5% (95% confidence interval [CI], 21Á2-86Á3%) and 23Á1% (95% CI, 5Á0-53Á8%) in paediatric patients with R/R FLT3-mutated AML and KMT2A-R ALL, respectively (Fig 1) . One patient with FLT3-mutated AML achieved a complete remission with incomplete count recovery on day 14; she discontinued midostaurin therapy on day 64 but remained in remission until her last response assessment (day 67), received a haematopoietic stem cell transplant (day 76), and was alive on day 960. In patients with FLT3-mutated AML and KMT2A-R ALL, median time to response was 14 (range, 8-22) days and 8 (range, 3-8 ) days, respectively; median overall survival (95% CI) was 3Á7 (2Á7-8Á3) months and 1Á4 (1Á0-2Á9) months, respectively ( Figure S3 ).
This study was the first to evaluate the safety, efficacy, and pharmacokinetics (Appendix S1) of oral midostaurin solution in children. The RDE was set at 60 mg/m 2 bid for the 2 age groups. Single-agent midostaurin showed limited clinical activity in these children with heavily pretreated FLT3mutated AML or KMT2A-R ALL. Despite preclinical data suggesting that midostaurin sensitivity in infant KMT2A-R ALL overexpressing FLT3 was similar to that in FLT3mutated AML (Stam et al, 2007) , single-agent midostaurin showed no clinical activity in children with R/R KMT2A-R ALL, possibly because overexpression of FLT3 alone is not sufficient to drive the disease or because FLT3 was not inhibited enough at the doses tested to elicit responses. Future studies should aim to understand the kinetics of FLT3 mutations between diagnosis and relapse, as they present an important prognostic factor for patients with AML. The unmet need in paediatric patients with R/R FLT3-mutant AML or KMT2A-R ALL is high. Because midostaurin plus chemotherapy demonstrated clinical benefit in adults with FLT3-mutated AML and single-agent midostaurin was generally well tolerated in paediatric patients, midostaurin will be evaluated in combination with chemotherapy in paediatric patients with FLT3-mutated AML.
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